Atalanta Therapeutics

Atalanta Therapeutics

Biotechnology Research

Boston, MA 6,546 followers

Pioneering RNAi treatments for neurodegenerative diseases

About us

We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Boston, MA
Type
Privately Held

Locations

Employees at Atalanta Therapeutics

Updates

Similar pages

Browse jobs

Funding

Atalanta Therapeutics 1 total round

Last Round

Series A

US$ 110.0M

See more info on crunchbase